Date:10.03.2017, 20:21 The development of medicines using newer, innovative nanotechnology techniques may raise new challenges for the Agency in the future. These include discussions on whether the current regulatory framework is appropriate for these medicines and whether existing guidelines and requirements on the way the medicines are assessed and monitored are adequate. Activities at the European Medicines Agency. The European Medicines Agency follows the latest developments in nanotechnology that are relevant to the development of medicines. Recommendations from the Agency's. Committee for Medicinal Products for Human Use (CHMP ) have already led to the approval of a number of medicines based on nanotechnology. In medicine, nanotechnology has only partially been exploited. It is being investigated as a way to improve the properties of medicines, such as their solubility or stability, and to develop medicines that may provide new ways to: deliver medicines to the body; target medicines in the body more accurately; diagnose and treat diseases; support the regeneration of cells and tissues. International workshops on nanomedicines The Agency organises workshops on nanomedicines to explore the scientific aspects of nanomedicines and enable the sharing of experience at an international level, in order to assist future developments in the field: First international workshop on nanomedicines See all ratings 16 ratings 4 ratings 2 ratings 4 ratings 5 ratings).
A narrative essay would be easier to negotiate through because a narrative essay is simply a narrative of the novel interspersed with the writers own opinions. The book report, the simplest of all, would merely summarize the novel.